YRDC

Summary

YRDC (yrdC N6-threonylcarbamoyltransferase domain containing, HGNC:28905) is a protein-coding gene on chromosome 1p34.3, encoding Threonylcarbamoyl-AMP synthase (Q86U90). Cytoplasmic and mitochondrial threonylcarbamoyl-AMP synthase required for the formation of a threonylcarbamoyl group on adenosine at position 37 (t(6)A37) in tRNAs that read codons beginning with adenine. It is a selective cancer dependency (DepMap: 86.8% of cell lines).

Enables L-threonylcarbamoyladenylate synthase. Involved in tRNA threonylcarbamoyladenosine modification. Acts upstream of or within negative regulation of transport. Is active in mitochondrion. Implicated in Galloway-Mowat syndrome.

Source: NCBI Gene 79693 — RefSeq curated summary.

At a glance

• Gene–disease (curated): Galloway-Mowat syndrome 10 (Strong, GenCC)
• GWAS associations: 1
• Clinical variants (ClinVar): 59 total — 3 pathogenic
• Phenotypes (HPO): 43
• Cancer dependency (DepMap): dependent in 86.8% of screened cell lines
• MANE Select transcript: NM_024640

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28905
Approved symbol	YRDC
Name	yrdC N6-threonylcarbamoyltransferase domain containing
Location	1p34.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ23476, IRIP, SUA5
Ensembl gene	ENSG00000196449
Ensembl biotype	protein_coding
OMIM	612276
Entrez	79693

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000373044, ENST00000882854

RefSeq mRNA: 1 — MANE Select: NM_024640 NM_024640

CCDS: CCDS30675

Canonical transcript exons

ENST00000373044 — 5 exons

Exon	Start	End
ENSE00001403024	37807101	37807215
ENSE00001423765	37806857	37806976
ENSE00001426285	37804302	37804444
ENSE00001459396	37802945	37803997
ENSE00001459397	37807792	37808208

Expression profiles

Bgee: expression breadth ubiquitous, 255 present calls, max score 93.26.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 18.2990 / max 446.2443, expressed in 1812 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
11804	15.8935	1806
11803	2.2773	1148
11802	0.1282	47

Top tissues by expression

272 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
gingival epithelium	UBERON:0001949	93.26	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	91.72	gold quality
islet of Langerhans	UBERON:0000006	90.54	gold quality
gingiva	UBERON:0001828	89.85	gold quality
esophagus squamous epithelium	UBERON:0006920	89.09	gold quality
amniotic fluid	UBERON:0000173	88.68	gold quality
squamous epithelium	UBERON:0006914	88.60	gold quality
tongue squamous epithelium	UBERON:0006919	88.24	silver quality
palpebral conjunctiva	UBERON:0001812	87.03	gold quality
nephron tubule	UBERON:0001231	86.25	gold quality
endothelial cell	CL:0000115	86.06	gold quality
epithelium of esophagus	UBERON:0001976	85.76	gold quality
mononuclear cell	CL:0000842	85.44	gold quality
monocyte	CL:0000576	85.43	gold quality
Brodmann (1909) area 23	UBERON:0013554	85.30	gold quality
leukocyte	CL:0000738	85.14	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.97	gold quality
upper leg skin	UBERON:0004262	84.80	gold quality
pancreas	UBERON:0001264	84.48	gold quality
esophagus mucosa	UBERON:0002469	83.54	gold quality
mucosa of transverse colon	UBERON:0004991	83.54	gold quality
placenta	UBERON:0001987	83.39	gold quality
cortical plate	UBERON:0005343	83.27	gold quality
skin of abdomen	UBERON:0001416	83.03	gold quality
rectum	UBERON:0001052	82.97	gold quality
metanephric glomerulus	UBERON:0004736	82.97	gold quality
lower lobe of lung	UBERON:0008949	82.97	gold quality
renal glomerulus	UBERON:0000074	82.87	gold quality
right testis	UBERON:0004534	82.78	gold quality
middle temporal gyrus	UBERON:0002771	82.69	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.11

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

54 targeting YRDC, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-15A-5P	99.90	72.80	2787
HSA-MIR-15B-5P	99.90	72.78	2798
HSA-MIR-16-5P	99.90	72.80	2780
HSA-MIR-195-5P	99.90	72.81	2805
HSA-MIR-424-5P	99.89	71.90	2641
HSA-MIR-6838-5P	99.89	71.94	2690
HSA-MIR-3065-3P	99.87	70.25	1407
HSA-MIR-5003-3P	99.85	69.29	2517
HSA-MIR-3121-3P	99.82	71.96	3630
HSA-MIR-4530	99.69	66.47	1509
HSA-MIR-466	99.67	70.85	2863
HSA-MIR-6757-3P	99.63	66.88	1089
HSA-MIR-24-3P	99.59	69.97	1934
HSA-MIR-4524A-5P	99.57	71.73	1193
HSA-MIR-4524B-5P	99.57	71.68	1195
HSA-MIR-4753-5P	99.54	68.51	1356
HSA-MIR-4708-3P	99.51	67.99	870
HSA-MIR-365A-3P	99.43	70.02	836
HSA-MIR-365B-3P	99.43	70.02	836
HSA-MIR-150-3P	99.43	70.51	920

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 86.8% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 6)

• a novel cDNA that encodes a putative human protein with yrdC domain (PMID:12730717)
• hIRIP expression can regulate cargo assembly and function of efflux transporters, including P-glycoprotein, which mediates one of the most common mechanisms of the multidrug resistance (PMID:19279227)
• YrdC promoted the progression of HCC. (PMID:30978526)
• Mutations in YRDC cause an extremely severe form of Galloway-Mowat syndrome (GAMOS), an autosomal recessive disease characterized by early-onset steroid-resistant nephrotic syndrome and microcephaly. (PMID:31481669)
• Biallelic variants in YRDC cause a developmental disorder with progeroid features. (PMID:34545459)
• RNA Structural Dynamics Modulate EGFR-TKI Resistance Through Controlling YRDC Translation in NSCLC Cells. (PMID:36435452)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	yrdc	ENSDARG00000041428
mus_musculus	Yrdc	ENSMUSG00000028889
rattus_norvegicus	Yrdc	ENSRNOG00000025424
drosophila_melanogaster	Tcs1	FBGN0061361
caenorhabditis_elegans		WBGENE00012997

Protein

Protein identifiers

Threonylcarbamoyl-AMP synthase — Q86U90 (reviewed: Q86U90)

Alternative names: Dopamine receptor-interacting protein 3, Ischemia/reperfusion-inducible protein homolog

All UniProt accessions (1): Q86U90

UniProt curated annotations — full annotation on UniProt →

Function. Cytoplasmic and mitochondrial threonylcarbamoyl-AMP synthase required for the formation of a threonylcarbamoyl group on adenosine at position 37 (t(6)A37) in tRNAs that read codons beginning with adenine. Catalyzes the conversion of L-threonine, HCO(3)(-)/CO(2) and ATP to give threonylcarbamoyl-AMP (TC-AMP) as the acyladenylate intermediate, with the release of diphosphate. Participates in t(6)A37 formation in cytoplasmic and mitochondrial tRNAs. May regulate the activity of some transporters.

Subunit / interactions. Interacts with RSC1A1.

Subcellular location. Cytoplasm. Mitochondrion. Cell membrane.

Tissue specificity. Ubiquitously expressed.

Disease relevance. Galloway-Mowat syndrome 10 (GAMOS10) [MIM:619609] A form of Galloway-Mowat syndrome, a severe renal-neurological disease characterized by early-onset nephrotic syndrome associated with microcephaly, central nervous system abnormalities, developmental delays, and a propensity for seizures. Brain anomalies include gyration defects ranging from lissencephaly to pachygyria and polymicrogyria, and cerebellar hypoplasia. Most patients show facial dysmorphism characterized by a small, narrow forehead, large/floppy ears, deep-set eyes, and micrognathia. Additional variable features are visual impairment and arachnodactyly. Most patients die in early childhood. GAMOS10 is an autosomal recessive form with fatal outcome. Patients manifest congenital hypothyroidism in addition to neurologic, renal and dysmorphic features. The disease is caused by variants affecting the gene represented in this entry.

Domain organisation. The mitochondrial targeting sequence (MTS) is weak and only mediates import of a small fraction of YRDC in mitochondria.

Similarity. Belongs to the SUA5 family.

RefSeq proteins (1): NP_078916* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006070	Sua5-like_dom	Domain
IPR017945	DHBP_synth_RibB-like_a/b_dom	Homologous_superfamily
IPR050156	TC-AMP_synthase_SUA5	Family

Pfam: PF01300

Catalyzed reactions (Rhea), 1 shown:

• L-threonine + hydrogencarbonate + ATP = L-threonylcarbamoyladenylate + diphosphate + H2O (RHEA:36407)

UniProt features (10 total): sequence variant 3, mutagenesis site 2, transit peptide 1, chain 1, domain 1, region of interest 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q86U90-F1	83.30	0.69

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 60

Mutagenesis-validated functional residues (2):

Position	Phenotype
15–17	improved mitochondrial targeting sequence (mts), leading to increased import into mitochondria.
17	improved mitochondrial targeting sequence (mts), leading to increased import into mitochondria.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-6787450	tRNA modification in the mitochondrion

MSigDB gene sets: 312 (showing top): HNF3ALPHA_Q6, NKX25_02, GOBP_TRNA_METABOLIC_PROCESS, LHX3_01, NAGASHIMA_NRG1_SIGNALING_UP, GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_BLUE_UP, CEBP_Q2, NKX62_Q2, OSWALD_HEMATOPOIETIC_STEM_CELL_IN_COLLAGEN_GEL_UP, GOBP_NEGATIVE_REGULATION_OF_TRANSPORT, SRF_C, GOBP_RNA_MODIFICATION, BRN2_01, IRF1_Q6, WTGAAAT_UNKNOWN

GO Biological Process (4): tRNA threonylcarbamoyladenosine modification (GO:0002949), regulation of translational fidelity (GO:0006450), negative regulation of transport (GO:0051051), mitochondrial tRNA modification (GO:0070900)

GO Molecular Function (6): tRNA binding (GO:0000049), double-stranded RNA binding (GO:0003725), nucleotidyltransferase activity (GO:0016779), L-threonylcarbamoyladenylate synthase activity (GO:0061710), protein binding (GO:0005515), transferase activity (GO:0016740)

GO Cellular Component (5): cytoplasm (GO:0005737), mitochondrion (GO:0005739), mitochondrial matrix (GO:0005759), plasma membrane (GO:0005886), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
tRNA processing	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
tRNA modification	2
mitochondrion	2
RNA binding	2
cellular anatomical structure	2
regulation of biological quality	1
transport	1
negative regulation of biological process	1
regulation of transport	1
mitochondrial tRNA processing	1
mitochondrial RNA modification	1
transferase activity, transferring phosphorus-containing groups	1
nucleotidyltransferase activity	1
binding	1
catalytic activity	1
intracellular anatomical structure	1
cytoplasm	1
intracellular membrane-bounded organelle	1
intracellular organelle lumen	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

1524 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
YRDC	OSGEPL1	Q9H4B0	943
YRDC	RBBP9	O75884	895
YRDC	TPRKB	Q9Y3C4	874
YRDC	Q92681	Q92681	873
YRDC	OSGEP	Q9NPF4	872
YRDC	LAGE3	Q14657	846
YRDC	TP53RK	Q96S44	839
YRDC	SLC6A2	P23975	774
YRDC	SLC22A6	Q4U2R8	771
YRDC	GON7	Q9BXV9	763
YRDC	TRIT1	Q9H3H1	693
YRDC	SLC22A2	O15244	686
YRDC	SLC22A3	O75751	668
YRDC	TRMT5	Q32P41	666
YRDC	CDK5RAP1	Q96SZ6	560

IntAct

24 interactions, top by confidence:

A	B	Type	Score
DNALI1	YRDC	psi-mi:“MI:0915”(physical association)	0.560
BAG6	YRDC	psi-mi:“MI:0915”(physical association)	0.560
KLF11	YRDC	psi-mi:“MI:0915”(physical association)	0.560
NUP58	YRDC	psi-mi:“MI:0915”(physical association)	0.560
SPIN2B	WDHD1	psi-mi:“MI:0914”(association)	0.530
SPIN1	PAX3	psi-mi:“MI:0914”(association)	0.530
KHDRBS2	SUPT5H	psi-mi:“MI:0914”(association)	0.350
FBLN5	ZNF320	psi-mi:“MI:0914”(association)	0.350
APBA1	KIF2A	psi-mi:“MI:0914”(association)	0.350
NTNG1	UBA6	psi-mi:“MI:0914”(association)	0.350
NECAP2	INPPL1	psi-mi:“MI:0914”(association)	0.350
CALM1	PLEKHG3	psi-mi:“MI:0914”(association)	0.350

BioGRID (36): YRDC (Affinity Capture-MS), YRDC (Affinity Capture-MS), YRDC (Biochemical Activity), YRDC (Affinity Capture-MS), YRDC (Affinity Capture-MS), YRDC (Affinity Capture-MS), YRDC (Affinity Capture-MS), YRDC (Affinity Capture-MS), YRDC (Affinity Capture-MS), YRDC (Affinity Capture-MS), YRDC (Negative Genetic), YRDC (Positive Genetic), YRDC (Affinity Capture-MS), YRDC (Affinity Capture-MS), YRDC (Affinity Capture-MS)

ESM2 similar proteins: A0JPF9, A4D126, D2GU20, E1BCH6, E9PYK3, O35465, O60888, O75425, O75808, P43896, P47823, P69678, P97812, Q0VC80, Q13144, Q14318, Q27J81, Q2VPK5, Q3B7U9, Q3TX08, Q3U269, Q496Y0, Q499R4, Q5ND52, Q5RJG7, Q5S6T3, Q64350, Q66KY3, Q6MGD0, Q6ZT62, Q7T0X7, Q7T3C3, Q86U90, Q8BGG6, Q8BYH7, Q8CHW4, Q8HXH0, Q8IYL2, Q91YR5, Q96EN8

Diamond homologs: A1S579, A5GS00, A5VFP2, A6QGV5, A7X283, A8F4E8, A8MC09, A9MHS1, O07451, P28156, P30131, P40596, P45805, P84142, Q02987, Q0VC80, Q0VTD8, Q135C2, Q13J37, Q1IKJ2, Q1MFT8, Q1QLD8, Q211P4, Q2FH34, Q2FYM9, Q2RQZ4, Q2S0V7, Q2YY14, Q3SRU5, Q3U5F4, Q43950, Q499R4, Q55638, Q58123, Q5E4P9, Q5HG16, Q5JDG7, Q5SKS6, Q6G9F7, Q6GH04

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

59 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	3
Likely pathogenic	0
Uncertain significance	29
Likely benign	16
Benign	3

Top pathogenic / likely-pathogenic (3)

Variant ID	HGVS	Classification
1321213	NM_024640.4(YRDC):c.721_724del (p.Val241fs)	Pathogenic
1321214	NM_024640.4(YRDC):c.791TCC[1] (p.Leu265del)	Pathogenic
1321215	NM_024640.4(YRDC):c.662T>C (p.Ile221Thr)	Pathogenic

SpliceAI

440 predictions. Top by Δscore:

Variant	Effect	Δscore
1:37803998:C:CC	acceptor_gain	1.0000
1:37804295:GACTT:G	donor_loss	1.0000
1:37804296:ACTT:A	donor_loss	1.0000
1:37804297:CTTAC:C	donor_loss	1.0000
1:37804298:TTA:T	donor_loss	1.0000
1:37804299:TACC:T	donor_loss	1.0000
1:37804300:A:AC	donor_gain	1.0000
1:37804300:ACCAG:A	donor_gain	1.0000
1:37804301:C:CA	donor_loss	1.0000
1:37804301:C:CG	donor_gain	1.0000
1:37804301:CCAG:C	donor_gain	1.0000
1:37804301:CCAGC:C	donor_gain	1.0000
1:37804442:CTC:C	acceptor_gain	1.0000
1:37804445:C:CC	acceptor_gain	1.0000
1:37804445:CTG:C	acceptor_loss	1.0000
1:37806852:CTCA:C	donor_loss	1.0000
1:37806853:TCACC:T	donor_loss	1.0000
1:37806854:CACC:C	donor_loss	1.0000
1:37806973:CAAG:C	acceptor_gain	1.0000
1:37806977:C:CC	acceptor_gain	1.0000
1:37807094:GACTC:G	donor_loss	1.0000
1:37807095:ACTCA:A	donor_loss	1.0000
1:37807096:CTCAC:C	donor_loss	1.0000
1:37807097:TCA:T	donor_loss	1.0000
1:37807098:CA:C	donor_loss	1.0000
1:37807099:A:AC	donor_gain	1.0000
1:37807099:ACAGG:A	donor_gain	1.0000
1:37807100:C:CT	donor_gain	1.0000
1:37807100:CA:C	donor_gain	1.0000
1:37807100:CAG:C	donor_gain	1.0000

AlphaMissense

1766 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:37806896:A:C	S195R	0.999
1:37806896:A:T	S195R	0.999
1:37806898:T:G	S195R	0.999
1:37804347:A:T	V241D	0.998
1:37807851:C:A	K110N	0.998
1:37807851:C:G	K110N	0.998
1:37807918:T:A	D88V	0.998
1:37804439:G:C	F210L	0.997
1:37804439:G:T	F210L	0.997
1:37804440:A:G	F210S	0.997
1:37804441:A:G	F210L	0.997
1:37806894:G:T	A196D	0.997
1:37806897:C:T	S195N	0.997
1:37807906:C:T	G92D	0.997
1:37807919:C:A	D88Y	0.997
1:37807919:C:G	D88H	0.997
1:37807927:A:T	V85D	0.997
1:37807930:G:T	A84D	0.997
1:37806897:C:A	S195I	0.996
1:37806906:G:T	A192D	0.996
1:37807113:G:C	N164K	0.996
1:37807113:G:T	N164K	0.996
1:37807820:A:G	C121R	0.996
1:37804322:A:C	F249L	0.995
1:37804322:A:T	F249L	0.995
1:37804324:A:G	F249L	0.995
1:37804410:A:T	V220D	0.995
1:37806890:G:C	N197K	0.995
1:37806890:G:T	N197K	0.995
1:37806903:A:G	L193P	0.995

dbSNP variants (sampled 300 via entrez): RS1001173441 (1:37806473 G>A,C), RS1001204513 (1:37806668 G>A), RS10015 (1:37802983 G>A), RS1002263352 (1:37805378 C>T), RS1002294536 (1:37805119 G>A), RS1003104554 (1:37808586 C>A,T), RS1003294692 (1:37803688 C>G), RS1003420581 (1:37809040 A>C,G), RS1003472677 (1:37809824 G>A,C), RS1004159505 (1:37809827 C>T), RS1004190639 (1:37810134 C>T), RS1004492793 (1:37808265 G>C,T), RS1004523861 (1:37808414 G>A), RS1004556513 (1:37808600 C>G), RS1004643690 (1:37809278 A>G)

Disease associations

OMIM: gene MIM:612276 | disease phenotypes: MIM:619609

GenCC curated gene-disease

Disease	Classification	Inheritance
Galloway-Mowat syndrome 10	Strong	Autosomal recessive

Mondo (1): Galloway-Mowat syndrome 10 (MONDO:0030476)

Orphanet (0):

HPO phenotypes

43 total (30 of 43 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000093	Proteinuria
HP:0000100	Nephrotic syndrome
HP:0000112	Nephropathy
HP:0000164	Abnormality of the dentition
HP:0000252	Microcephaly
HP:0000316	Hypertelorism
HP:0000347	Micrognathia
HP:0000400	Macrotia
HP:0000601	Hypotelorism
HP:0000851	Congenital hypothyroidism
HP:0001166	Arachnodactyly
HP:0001181	Adducted thumb
HP:0001250	Seizure
HP:0001252	Hypotonia
HP:0001263	Global developmental delay
HP:0001272	Cerebellar atrophy
HP:0001276	Hypertonia
HP:0001302	Pachygyria
HP:0001336	Myoclonus
HP:0001511	Intrauterine growth retardation
HP:0001622	Premature birth
HP:0001967	Diffuse mesangial sclerosis
HP:0002036	Hiatus hernia
HP:0002059	Cerebral atrophy
HP:0002188	Delayed CNS myelination
HP:0002269	Abnormality of neuronal migration
HP:0002353	EEG abnormality
HP:0002410	Aqueductal stenosis
HP:0003577	Congenital onset

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST003476_2	Eyebrow thickness	7.000000e-06

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

59 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Cyclosporine	increases expression	3
sodium arsenite	affects cotreatment, decreases expression, increases expression	2
Air Pollutants	increases abundance, increases expression, decreases expression	2
Estradiol	affects expression, increases expression	2
Tobacco Smoke Pollution	increases expression	2
Valproic Acid	affects expression, increases expression	2
Asbestos, Crocidolite	decreases expression, increases expression	2
Particulate Matter	increases expression, decreases expression, increases abundance	2
FR900359	affects phosphorylation	1
triphenyl phosphate	affects expression	1
bisphenol A	affects expression	1
beta-lapachone	increases expression	1
afimoxifene	decreases reaction, increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
potassium chromate(VI)	affects cotreatment, increases expression	1
beta-methylcholine	affects expression	1
epigallocatechin gallate	affects cotreatment, increases expression	1
di-n-butylphosphoric acid	affects expression	1
pentabromodiphenyl ether	increases expression	1
perfluoro-n-nonanoic acid	increases expression	1
monomethylarsonous acid	increases expression	1
K 7174	increases expression	1
erucylphospho-N,N,N-trimethylpropylammonium	increases expression	1
abrine	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	increases expression	1
elesclomol	increases expression	1
(4-amino-1,4-dihydro-3-(2-pyridyl)-5-thioxo-1,2,4-triazole)copper(II)	increases expression	1
jinfukang	affects cotreatment, decreases expression	1
PCI 5002	affects cotreatment, increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.